Exparel sales up 22.4% after CMS offers coverage — 3 quick insights

For the first quarter, Pacira BioSciences reported record sales of Exparel, a non-opioid pain management drug that became eligible for separate Medicare reimbursement in ASCs as of Jan. 1.

Advertisement

Three quick insights:

1. Net sales of Exparel reached $90.6 million in the first quarter of 2019, a year-over-year increase of 22.4 percent.

2. ASCs and oral surgery centers were the key drivers of Exparel utilization.

3. Pacira’s total first-quarter revenues were $91.3 million, up from $74.6 million in the first quarter of 2018.

More articles on anesthesia:
SouthEast Eye Specialists adds Drs. JD Bonner, Will Whitmire — 3 insights
Happy 25th birthday Arizona Institute of Medicine and Surgery — 4 insights
Meet Chesapeake Urology’s newest specialist — 3 highlights

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Anesthesia

Advertisement

Comments are closed.